Philips takes testing POC to new heights with Magnotech solution
Wednesday 19 November 2008 Ashley Yeo - Editor

The POC sector is a relatively new departure for Philips in healthcare. The technology will underpin a new hand-held solution for monitoring drugs-of-abuse. Graphic: Philips

“POC has certainly not grown very fast recently,” according to Marcel van Kasteel, vice-president of Philips and CEO of Philips Handheld Immunoassays.

“The current world market is valued at some $3-4bn,” he told Clinica, “but it has the potential to reach $15bn.”

For that to happen, though, a structural change in the market will be needed, driven by the introduction of new technologies.

That is what Philips has in mind with its new nanoparticle and optical-based hand-held POC solution, which applies its unique, proprietary Magnotech technology.

The group is in fact developing two different POC platforms, based on saliva and blood. This platform technology, which was profiled exclusively to Clinica this week, will be unveiled by the group at Medica 2008, in Düsseldorf on November 19-22....

Clinica Issue 1327 – 14th November 2008 - is out now